Tesaro parts soared as much as 39 percent Friday upon a Bloomberg arrive that the pharmaceutical company will explore the opportunity of a sale.
This clock on exactly one week after the cancer drug company fell more than 20 percent during after-hours mty after the release of drug trial results for treatment of small stall lung cancer. A spokesperson declined to comment.
The company is working with economic advisers to examine the deal, and the company could still remain barring, the Bloomberg story said. The financial advisers also have telephone other potential buyers.
Tesaro also explored a sale in May 2017, but it did not stop by to a close. Shares then fell more than 11 percent during that experience.
The company was founded in 2010 and went public in 2012. Its first panacea, Varubi, was approved by the US Food and Drug Administration in October 2015. It’s tempered to to treat chemotherapy side effects, such as nausea and vomiting. It’s other cancer soporific Zejula has been struggling.
Shares are down 68 percent this year.
This tall tale is developing. Please check back for updates.